Adjuvant interferon: extended follow-up times needed?

Lancet Oncol. 2011 May;12(5):419. doi: 10.1016/S1470-2045(11)70107-3.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Antineoplastic Agents / therapeutic use*
  • Chemotherapy, Adjuvant
  • Disease-Free Survival
  • Follow-Up Studies
  • Humans
  • Interferon alpha-2
  • Interferon-alpha / therapeutic use*
  • Melanoma / drug therapy*
  • Melanoma / mortality*
  • Melanoma / prevention & control
  • Randomized Controlled Trials as Topic
  • Recombinant Proteins
  • Secondary Prevention
  • Skin Neoplasms / drug therapy
  • Survival Analysis
  • Time Factors

Substances

  • Antineoplastic Agents
  • Interferon alpha-2
  • Interferon-alpha
  • Recombinant Proteins